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Objective. To assess treatment eﬃcacy and quality of life in women with stress urinary incontinence 3 years after treatment
with nonsurgical transurethral radiofrequency collagen denaturation. Methods. This prospective study included 139 women with
stress urinary incontinence due to bladder outlet hypermobility. Radiofrequency collagen denaturation was performed using local
anesthesia in an oﬃce setting. Assessments included incontinence quality of life (I-QOL) and urogenital distress inventory (UDI-
6) instruments. Results. In total, 139 women were enrolled and 136 women were treated (mean age, 47 years). At 36 months,
intent-to-treat analysis (n = 139) revealed signiﬁcant improvements in quality of life. Mean I-QOL score improved 17 points from
baseline (P = .0004), while mean UDI-6 score improved (decreased) 19 points (P = .0005). Conclusions. Transurethral collagen
denaturation is a low-risk, oﬃce-based procedure that results in durable quality-of-life improvements in a signiﬁcant proportion
of women for as long as 3 years.
1.Introduction
The management of female SUI [1, 2]c o n t i n u e st oe v o l v e
with improvements in both our understanding of the conti-
nentmechanism[3]andwithimprovementsinthetechnolo-
gies and methods used to treat incontinence. Of particular
note, the introduction of synthetic slings in the mid 1990s
and the widespread use of urodynamics have contributed
to improved management of patients who experience SUI.
However, although SUI remains a pervasive problem in the
female population with a prevalence of 25% to 30% [4],
fewer than 5% of US women diagnosed with SUI opt for
surgical intervention.
Despite its prevalence and the associated distress, embar-
rassment, and diminished quality of life (QOL), many wom-
en who experience symptoms of SUI delay or do not seek
medical treatment. A recent survey found that only 15%
of women aged 40 years or older with SUI sought medical
treatmentfortheirsymptoms[5].Althoughpersonalreasons
for not seeking treatment vary among individual women,
they include fear of the risks and life disruptions associated
with current surgical options [6], and an interest in less-
invasive treatments oﬀering symptom improvement versus
cure is growing [7].
In keeping with this trend, and reﬂecting the growing
interest by physicians in procedures that can be performed
in-oﬃce, this study reports on the 36-month durability of an
incision-free treatmentfor SUI primarily intended for symp-
tomrelief.Thistreatment,whichistypicallyperformedinan
oﬃce setting [8, 9] using local anesthesia (Renessa; Novasys
Medical, Inc, Newark, Calif, USA) received FDA clearance
in 2005 following a randomized, sham-controlled study by2 Advances in Urology
Appell et al. [10] that demonstrated both safety and eﬃcacy
at 12-month after treatment. The introduction of this tech-
nology has meant that patients now have a convenient one-
time, in-oﬃce, nonsurgical treatment option for the man-
agement of their SUI.
Expectations about outcomes (expressed in terms rele-
vant to women’s QOL) inﬂuence the choice of treatment
onceshedoesseektreatment,sinceeachtherapeuticoptionis
associated with varying degrees of invasiveness, eﬀectiveness,
and expected impact on QOL both during recovery and aft-
erward. As such, most studies of SUI therapies now include
both objective and subjective measures, such as validated
QOLquestionnaires,whichmayalsobeusedinclinicalprac-
tice [11].
Noninvasiveconservative(behavioral)optionsorphysio-
therapy are typically selected as ﬁrst-line therapies. Although
such interventions can be eﬀective and can substantially
improve a patient’s QOL [12–15], the onset of beneﬁts
may be prolonged, and successful outcomes depend on the
patient’s understanding, training, motivation, and persis-
tence [13, 15, 16]. More passive treatment using devices such
as vaginal pessaries and cones/weights may also improve SUI
symptoms [17, 18].
C e r t a i nd r u g s ,s u c ha se s t r o g e n s ,α-adrenergic receptor
agonists, β-adrenergic receptor antagonists, tricyclic antide-
pressants, anticholinergics, and a serotonin-norepinephrine
reuptake inhibitor are prescribed oﬀ l a b e lb ys o m eU S
physicians, but they are not consistently eﬀective and none is
currentlyapprovedbytheUSFoodandDrugAdministration
(FDA) for the treatment of SUI [6]. Additionally, as with any
drug,theremaybeariskforlong-termsideeﬀects.Inastudy
byRobinsonetal.,only14%ofwomensurveyedwerewilling
to accept long-term drug therapy [7].
Periurethral injection of bulking agents is a nonsurgical
treatment option that may be used in women with SUI due
to intrinsic sphincter deﬁciency (ISD). While most studies of
bulking agentsreport good initial eﬃcacyand improvements
in QOL, the durability of eﬀect can decrease over time [12,
19] and may require repeated injections [12, 19, 20], The
newer synthetic agents may provide better durability than
collagen-based agents [21, 22]. Safety appears to be generally
good, but concerns exist about the long-term eﬀects of
repeated injections [12]. For example, ﬁbrosis and/or den-
ervation of the urethral sphincter from repeated injections
could interfere with the ability to perform subsequent sur-
gery for recurrent incontinence [12]. Additionally, some se-
rious adverse events, such as particle migration and mass
formation, have been reported with some synthetic bulking
agents [23–26].
Surgical procedures are popular treatment options that
can be safe and eﬀective, but none is without risks or side
eﬀects, and each requires a recovery period of several weeks
before the patient can return to normal daily activities.
Furthermore, voiding diﬃculties, detrusor overactivity, and
other adverse events are well-described complications fol-
lowing SUI surgery [27], and some synthetic sling materials
have been associated with erosion into the vagina or urinary
tract [12].
Table 1: Baseline characteristics of the study population.
Characteristic All enrolled patients
(N = 139)
Median age, y (range) 47 (26–87)
Median weight, lb (range) 160 (110–280)
Mean total I-QOL score (SE) 51.2 (1.7)
Mean UDI-6 score (SE) 52.7 (1.4)
Median leaks caused by activity (range)
Daily 2.9 (0–11)
Weekly 20 (0–80)
Pelvic organ prolapse stage, n (%)
Stage 0 45 (33%)
Stage 1 63 (45%)
Stage 2 29 (21%)
Stage 3 1 (0.7%)
Unknown 1 (0.7%)
I-QOL: Incontinence Quality of Life; UDI: Urogenital Distress Inventory.
Eﬀective results for the transurethral collagen denatura-
tion treatment have been previously reported [10, 28, 29],
thus the present study was prospectively designed to further
assess the durability of results at 36-month following the
procedure performed in the typical oﬃce-practice setting.
This paper describes a prospective analysis of treatment
eﬃcacy and impact on quality of life, primarily focused on
results at 36 months; however, results from previous time
points are also reported.
2.MaterialsandMethods
This 36-month, open-label, single-arm clinical trial was
conducted at multiple US physicians’ oﬃces to evaluate the
long-termsafetyandeﬃcacyoftransurethralradiofrequency
collagen denaturation. Women who were clinically diag-
nosed with SUI secondary to bladder outlet hypermobility
for 12 months or longer were eligible for inclusion. Clinical
evaluation and diagnosis were made by each investigator
based on diary data, quality of life questionnaires, in-oﬃce
stress pad-weight test, patient history, and physical exami-
nation. Urodynamic studies were not required but were em-
ployed at the investigators’ discretion if determined to be
necessary to make or conﬁrm a clinical diagnosis. Partici-
pants,aged18yearsorolderatbaseline,hadfailedtraditional
nonsurgical therapy and were not candidates for surgical
treatment (including women who wished to avoid surgery)
and had the ability to complete all study requirements. Pa-
tientsweredetermined tohavefailedtraditional conservative
therapy if they indicated that they tried and failed pelvic
muscle exercises, pharmacotherapy, or biofeedback. Exclu-
sion criteria included pregnancy, prior SUI surgery or bulk-
ing agent injection, leak point pressure less than 60cm H2O,
postvoid residual bladder volume greater than 50mL, stage
IVpelvicorganprolapse,and/oradiagnosisofdetrusorover-
activity or primarily urge incontinence.
As SUI is a clinical diagnosis, this study was designed
to be applicable to a general SUI population and to currentAdvances in Urology 3
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Figure 1: Patient disposition. ∗Two validated questionnaires, the incontinence quality of life and the urogenital distress inventory instru-
ments, were completed at 36 months.
Table 2: Stress Leaks per day per diary.
Visit Directly Evaluable Intent-to-Treat
N Mean ± SE N Mean ± SE
Baseline 136 3.16 ± 0.17 139 3.2 ± 0.17
12 months 65 2.01 ± 0.27 139 1.9 ± 0.21
24 months 43 1.92 ± 0.46 139 1.7 ± 0.45
36 months 40 1.45 ± 0.28 139 1.5 ± 0.27
Baseline—36 months 39 −2.13 ± 0.35 P<. 0001 139 −1.68 ± 0.31 P<. 0001
oﬃce-based clinical practice, thus clinical assessment was
used.
T h ep r o t o c o lw a sa p p r o v e db yW e s t e r nI R B( P r o t o c o l
number 20052168) in December 2005 and written informed
consent was provided by all study participants.
The majority of transurethral collagen denaturation
procedures were performed in the study physician’s oﬃce
using local anesthesia. Patients received a prophylactic oral
antibiotic (levoﬂoxacin 250mg or ciproﬂoxacin 500mg, or
appropriate alternative) 3 to 4 hours before treatment and
an oral sedative (diazepam 5 to 10mg or similar benzo-
diazepine)30to90minutesbeforehand.Patientswereplaced
in the lithotomy position, with a return “grounding” pad
applied to the skin, and given a periurethral lidocaine
block (10cc of 2% lidocaine with epinephrine 1:100000
or 1:200000). The radiofrequency probe was then inserted
transurethrally until the tip was positioned within the blad-
der lumen, and the balloon at the probe tip was insuﬄated.
From the probe shaft, four 23-gauge nickel-titanium needle
electrodes were deployed. Using deployment markings on4 Advances in Urology
Table 3: 50% Reduction in leaks per day based on diary entries.
Directly Evaluable Intent-to-Treat∗
12 months 54% (34/63) 55% (74/135)
24 months 64% (27/42) 64% (86/135)
36 months 62% (24/39) 60% (81/135)
∗Note: 4 patients had 0 leaks at baseline, thus could not be evaluated for
percent change from baseline.
the probe to guide rotation, and the balloon and needles
to position the device, radiofrequency energy was delivered
through the needles for nine 60-second cycles as sterile,
room-temperaturewaterirrigated the urethralmucosa.Dur-
ing each cycle, the submucosa surrounding the 4 needle tips
was heated to 65◦C, producing local collagen denaturation
at 36 sites circumferentially around the bladder neck and
proximal urethra without tissue necrosis [10, 30]. Upon
completion of the ﬁnal cycle, the needles were retracted into
the shaft, the balloon was deﬂated, and the probe was re-
moved. The patient was asked to void following the proce-
dure, which was typically completed in about 30 minutes.
Most patients left the physician’s oﬃce within 1 hour after
treatment and returned to normal activities the same day or
the next.
Reﬂecting the study’s goal of measuring durability of
the improvement in symptom relief using a metric relevant
and important to patients, the primary eﬃcacy end point
was that at least 60% of patients would experience a 50%
or greater reduction from baseline in stress incontinence
episodes at 12 months. As previously reported, this was
achieved [28]. Secondary measures included changes in
incontinence impact on QOL assessed using the validated
incontinence qualify of life (I-QOL) instrument [31]a n d
on the urogenital distress inventory (UDI-6) scale. Each of
these assessments was conducted at baseline and at 3, 6, 12,
18, 24, and 36 months. If patients did not return to the
physician’soﬃceforthe36-monthvisit,theywerecontacted,
per protocol, and asked to complete the I-QOL and UDI-6
instruments via telephone.
Of particular interest are results obtained using intent-
to-treat (ITT) analysis, wherein data from all 139 patients
initially enrolled are included. For such analysis, the missing
value strategies employed were as follows: (1) for intermit-
tentmissingdata,themeanchangefromthenearestavailable
adjacent time point prior to the time point with missing data
from among those patients with data present for both time
points was calculated; this same change was then applied
to the missing data point to obtain an imputed data value;
(2) for truncated missing data, wherein a patient was not
available beyond a certain time before study completion,
multipleimputations(MIs)wereemployed.Alogisticregres-
sion model was ﬁt to estimate the probability of a patient
having a missing data point (propensity score). Baseline
characteristics in the model included age, weight, baseline
leaks associated with activity, pelvic prolapse stage, baseline
I-QOL score, and baseline UDI-6 score. Additionally, values
for the outcome of interest at all available follow-up time
points were included in the model. Patients who were similar
with respect to their probability of having a missing data
point were grouped together into 5 strata using quintiles
of the propensity score. Since the LR model includes both
baseline and available data, patients were grouped on both
theirbaselinefactorsandontheirsimilarityintrajectoryover
time for the outcome variable in question. Next the missing
data point was generated using an imputed value assigned
by randomly choosing a value from among those in the
same stratum from patients with nonmissing observations.
The procedure was repeated 20 times on the entire data set,
resulting in 20 diﬀerent complete data sets. Missing-value
estimates and the corresponding standard errors for each
outcome variable (e.g., mean change from baseline to 36
months) were then calculated from each of the 20 data sets
by combining the between and within imputation variance.
So the resulting estimate incorporates both the between
subject variability and the variability associated with the
imputation method to provide an overall unbiased missing-
value and standard error estimate that accounts for missing
data uncertainty and includes data from all 139 patients.
Mean changes from baseline at 36 months for I-QOL,
UDI-6, pad weight, leaks/day per bladder diaries, and daily
leaks due to activity obtained from case report forms were
assessed using a paired student’s t test. Over the extended
follow-up period, the percentages of patients were described
with (1) at least a 10-point improvement in I-QOL, (2) any
improvement in I-QOL, (3) at least a 50% reduction in pad
weight, (4) “dry” pads using the ICS convention for this def-
inition,and(5)atleasta50%reductioninleaksperdayusing
diary analysis. SAS version 9.1 (SAS; Cary, NC, USA) was
used to complete all analyses.
The incidence of device-related and of serious adverse
events were the primary safety end points.
3. Results
The study enrolled 139 women at 13 centers. Table 1 reports
baseline demographics and characteristics. Prior to treat-
ment, 1 patient withdrew consent and the remaining women
continued into the treatment phase. Two women were dis-
continued prior to undergoing transurethral collagen denat-
uration because of lidocaine reactions. The remaining 136
women underwent treatment (Figure 1). All 139 enrolled
women are included in the ITT analysis.
As shown in Figure 1, 20 patients were known by investi-
gators to have undergone subsequent surgery, and 3 patients
were lost to follow up when their study site closed. Of the
remaining 113 patients, 41 completed their scheduled in-
oﬃce evaluations at 36 months after treatment. Investigators
then attempted to contact the 72 remaining patients to ask
them to complete both I-QOL and UDI-6 quality-of-life
measures via telephone. Each pair of QOL surveys took
approximately 10 minutes to complete via telephone. Pre-
vious studies have validated the concordance of telephone
versus in-person QOL survey results [32, 33], including
results with the pelvic ﬂoor distress inventory, which is based
upon the UDI questionnaire [11].Advances in Urology 5
Table 4: Incontinence qualify of life questionnaire results.
Visit Directly Evaluable Intent-to-Treat
N Mean ± SE N Mean ± SE
Baseline 139 51.2 ± 1.7 139 51.2 ± 1.7
3 months 119 63.9 ± 2.2 139 63.4 ± 2.1
6 months 107 66.4 ± 2.5 139 65.0 ± 2.4
12 months 75 67.7 ± 3.0 139 65.3 ± 2.7
18 months 61 70.2 ± 3.3 139 68.3 ± 3.1
24 months 45 69.0 ± 4.0 139 65.8 ± 3.3
36 months 76 73.0 ± 3.0 139 67.7 ± 4.2
Baseline–36 months 76 21.0 ± 3.1 P<. 0001 139 16.5 ± 4.3 P = .0004
Table 5: Improvement in incontinence qualify of life questionnaire scores
>10-point improvement Any improvement
Visit Directly Evaluable Intent-to-Treat Directly Evaluable Intent-to-Treat
3 months 55% (65/119) 57% (79/139) 69% (82/119) 68% (95/139)
6 months 57% (61/107) 56% (78/139) 73% (78/107) 69% (96/139)
12 months 65% (49/75) 56% (78/139) 80% (60/75) 71% (99/139)
18 months 70% (43/61) 62% (81/139) 82% (50/61) 76% (105/139)
24 months 69% (31/45) 58% (81/139) 82% (37/45) 72% (100/139)
36 months 68% (52/76) 60% (84/139) 78% (59/76) 71% (99/139)
Table 6: Incontinence qualify of life questionnaire ≥10-point Im-
provement, imputed results by severity at baseline.
Visit Mild Moderate Severe
(n = 50) (n = 65) (n = 24)
3 months 42% (21) 60% (39) 79% (19)
6 months 36% (18) 62% (40) 83% (20)
12 months 34% (17) 63% (41) 83% (20)
18 months 32% (16) 78% (51) 79% (19)
24 months 38% (19) 66% (43) 79% (19)
36 months 36% (18) 69% (45) 88% (21)
Of the 72 patients contacted, 35 women responded and
completed the I-QOL and UDI-6 questionnaires. Thirty-
seven women could not be located and were thus considered
lost to follow up.
The baseline characteristics of women who underwent
treatment but failed to provide 36-month data did not diﬀer
from those who continued in the trial.
3.1. Eﬃcacy. Reduction in leaks from baseline was assessed
using a patient bladder diary (Tables 2 and 3). In the ITT
population, the estimated percentage of patients with a 50%
or greater reduction from baseline in leaks per day equaled
60%; the mean baseline of 3.2 leaks per day declined to an
estimated 1.5 leaks per day by month 36 (P = .001), contin-
uing the positive trend ﬁrst reported at 12 months [28].
I-QOL results are shown in Tables 4, 5,a n d6. For the
ITT population at 36 months, improvement from baseline
averaged 16.5 points (P = .0004), with an estimated 60% of
patients achieving at least a 10-point improvement in I-QOL
scores and 71% achieving some improvement. A 10-point
improvement in the I-QOL score has been shown to be
clinically meaningful and is associated with a 25% reduction
in pad weight and a 25% reduction in incontinence episodes
[34].
The ITT I-QOL results for estimated percentages of pa-
tients achieving at least a 10-point improvement were strati-
ﬁed by severe, moderate, and mild at baseline (0–30, 31–60,
61–90, resp.; Table 6). Among patients with moderate/severe
SUI baseline values, 74% had at least a 10-point improve-
ment in I-QOL scores.
With regard to UDI-6 results, the mean score at baseline
o f5 2 . 7d e c l i n e db y3 3 . 3i nt h eI T Tp o p u l a t i o na t3 6m o n t h s
(P = .0005, Table 7).
ResultsforpadweightaredescribedinTables8,9,and10.
For the ITT population, mean baseline pad weight decreased
from35.5gatbaselineto23.0g(P = 0.18),withanestimated
57% of patients achieving at least a 50% reduction in pad
weight. Deﬁning a “dry” pad as one weighing less than 1g,
35% of ITT patients were considered dry at 36 months.
To explore the impact of diﬀerent assumptions about
withdrawals and missing data, a sensitivity analysis was per-
formed for the key outcome variable success rates (Table 11).
This analysis used a multiple imputation method wherein
known surgery patients are always considered failures, with
each patient’s ﬁnal presurgery data carried forward. Multiple
imputation was then applied to all remaining truncated
data alternately treating the 37 patients lost to follow up as
successes and as failures. As expected, for the outcomes with
the most missing data, the range of possible outcomes was
wide, reﬂecting the limits of the two most extreme scenarios.
Since neither of these two extremes is likely to happen, the
multiple imputation method provides an appropriate esti-
mate of what is likely to be the correct value, located between6 Advances in Urology
Table 7: Urogenital distress inventory-6.
Visit Directly Evaluable Intent-to-Treat
N Mean ± SE N Mean ± SE
Baseline 139 52.7 ± 1.4 139 52.7 ± 1.4
3 months 118 37.2 ± 1.9 139 37.7 ± 1.8
6 months 108 35.6 ± 2.1 139 36.6 ± 1.9
12 months 75 35.1 ± 2.7 139 36.6 ± 2.5
18 months 60 33.7 ± 3.2 139 35.7 ± 3.1
24 months 45 30.4 ± 3.4 139 35.7 ± 4.0
36 months 75 30.1 ± 2.8 139 33.3 ± 4.8
Baseline—36 months 75 −22.6 ± 3.2 P<. 0001 139 −19.4 ± 5.0 P = .0005
Table 8: Pad weight.
Visit Directly Evaluable Intent-to-Treat
N Mean ± SE N Mean ± SE
Baseline 139 35.5 ± 3.4 139 35.5 ± 3.4
12 months 67 23.6 ± 5.4 139 21.2 ± 4.3
24 months 42 23.2 ± 7.2 139 29.6 ± 8.0
36 months 40 23.0 ± 6.7 139 23.0 ± 8.6
Baseline—36 months 40 −12.2 ± 8.3 P = .15∗ 139 −12.5 ± 9.1 P = .18
∗Per t-test, signed rank test P = .03. Two extreme observations are noted. One shows an increase of 196, and the next largest is 85.3.
Table 9: 50% Reduction in pad Weight∗.
Directly Evaluable Intent-to-Treat
12 months 70% (47/67) 68% (95/139)
24 months 69% (29/42) 62% (86/139)
36 months 63% (25/40) 57% (79/139)
∗It should be noted that 72 patients have no 12- to 36-month follow-up
data available. These patients also appear to diﬀer signiﬁcantly from those
with follow-up data in baseline characteristics in that they had generally less
severe symptoms. It is thus important to focus on the multiple imputation
results that include values for all patients, particularly for this outcome.
these extremes, reﬂecting both the observed data and the
variability of the estimate.
3.2. Safety. Transurethral collagen denaturation was shown
to be safe and well tolerated for at least 36 months after
treatment. Immediately following the procedure, about one-
third of patients were able to return to normal daily activities
within 1 day of treatment (most within a few hours), while
125 (91.9%) patients returned to normal activities within 2
days. At day 3, the most common adverse events included
dysuria (n = 7; 5.2%), urinary retention (n = 6; 4.4%), post-
procedure pain (n = 4; 2.9%), and urinary tract infection
(n = 4; 2.9%). These events were transient and resolved
quickly. One patient required an indwelling catheter for 24
hours. Average pain score reported on a 10-point visual ana-
log scale (VAS) was 1.6. At 12 months, one patient reported
an increase in leaking, which the investigator deemed as
probably related to treatment. Symptoms of urgency or urge
incontinence were reported by 8 patients; in 6 patients, these
symptoms resolved by 12 months, and in 1, by 25 months;
symptoms remained in 1 patient at 36 months.
Table 10: “Dry” Pad (<1g).
Directly Evaluable Intent-to-Treat
12 months 39% (26/67) 38% (53/139)
24 months 40% (17/42) 30% (42/139)
36 months 38% (15/40) 35% (49/139)
At 18 months, 1 patient experienced a myocardial infarc-
tion that was deemed by the investigator to be not related to
the procedure. At the 24-month visit, one patient reported
a dry cough that was deemed not related to the procedure,
and another patient reported a recurrence of SUI. No new
treatment-related adverse events were reported between 18
and 36 months.
4. Discussion
Results from this 36-month study of nonsurgical transur-
ethralcollagendenaturationinwomenwithSUIduetoblad-
der outlet hypermobility demonstrated the eﬃcacy, durabil-
ity, and safety of this procedure.
Validity studies have shown that both the I-QOL and the
UDI-6 questionnaires can be used successfully in both daily
practice and in clinical research, and that these instruments
reliably assess the impact of symptom severity on patient
quality-of-life [34–37]. One study showed that 2.5- and
6.3-point diﬀerences in I-QOL scores indicate signiﬁcant
improvement in clinical status, as demonstrated by a reduc-
tion in the frequency and severity of incontinence episodes
and by improvement in the patient’s global perception of
her condition [34]. A 10-point increase generally indicates a
patient’s perception of being “much better” and is associatedAdvances in Urology 7
Table 11: Analysis of results at 36 months, using diﬀerent assumptions about outcomes for patients with missing data.
I-QOL ↑≥10 pts
Moderate-severe
@ baseline
I-QOL ↑≥10pts
Any I-QOL
increase
50% reduction
in pad Weight
“Dry” pad
(<1g)
50% reduction
in leaks per day
Women with
data available at
3 years
68% (52/76) 75% (36/48) 78% (59/76) 63% (25/40) 38% (15/40) 62% (24/39)
Imputation: all
surgeries are
failures and all
LTF are failures
37% (52/139) 40% (36/89) 42% (58/139) 18% (25/139) 11% (15/139) 18% (24/135)
Imputation: all
surgeries are
failures and all
LTF are
successes
68% (95/139) 71% (63/89) 73% (101/139) 75% (104/139) 68% (94/139) 75% (101/135)
Multiple
imputation: all
surgeries are
failures, with
last observation
carried forward;
multiple
imputations
applied to
lost-to-followup
patients
56% (78/139) 69% (61/139) 65% (90/139) 47% (65/139) 25% (35/139) 42% (57/135)
with a 25% or more reduction in both the frequency and
severity of incontinence episodes. Studies of the UDI-6 show
that results correlate well with urodynamic diagnoses, while
additional studies have reported similar results in correlating
QOL instruments with quantitative measures [35, 38, 39].
In the present study, the signiﬁcantly reduced number
of leaks at 36 months versus baseline demonstrated durable
improvement at 36 months after treatment. Patient QOL
scores also improved signiﬁcantly from baseline, as shown
by favorable results in both the IQOL and UDI-6 scores,
indicating a signiﬁcant improvement in SUI symptoms.
There was an overall low incidence of adverse events through
36 months, with no serious procedure-related adverse events
noted at any time point. Patients reported a rapid return to
normal daily activities following the procedure.
Stratifying the baseline incontinence severity by I-QOL
and using a 10-point improvement (on a 100-point scale) as
an eﬃcacy criteria, both an earlier 12-month, randomized,
sham-controlled trial [10] and the current 36-month study
demonstrated the eﬀectiveness of this treatment in patients
with moderate to severe incontinence (baseline I-QOL score,
<60).Intheearlierstudy,74%ofpatientsachieveda10-point
IQOL improvement compared with 50% of patients who
underwent the matching sham treatment. At 36 months in
the present trial, a 10-point or greater I-QOL improvement
from baseline was again achieved by 74% of all patients with
this degree of baseline severity.
A limitation of this study includes the dropout rate with
regard to patients completing all of the in-oﬃce assessments.
Unfortunately, high dropout rates are very common in trials
of incontinence treatments. Recent publications have report-
ed retaining only approximately 50% of patients at 2 years
and 35% at 5 years (for primary outcomes) [40–44]. These
high dropout ratesarepossibly related topatients’ unwilling-
ness to subject themselves to the inconvenience and unpleas-
antness of evaluations such as UDS and pad weight tests
or the nuisance of recording bladder diaries. Anticipating
patient dropouts, the investigators in this study included the
option of administering questionnaires by phone to obtain
more complete data. Results are also reported on an ITT
basis, including all enrolled patients, following application
of a missing-value imputation technique appropriate for
long-term studies where the improvement rate changes over
time. Sensitivity analyses were also performed to explore
diﬀerences in outcomes based on best- and worst-case as-
sumptions regarding the outcomes of patients for whom no
data was available.
Data from patients who were known to have undergone
subsequent surgery showed that despite being considered
“treatment failures,” half of these patients (10/20) had re-
ported some level of improvement following transurethral
collagen denaturation. Additionally, if a patient’s intention
was to prolong the need for surgery and not to avoid surgery
altogether, the duration of time between the procedure and
surgery could have been viewed as a successful outcome.
Overall, results of the present study support and extend
those of previous studies of transurethral collagen denatura-
tion. It is a minimally invasive, safe procedure that can be
performed under local anesthesia in a physician’s oﬃce,
with negligible to minimal recovery time. Results from this8 Advances in Urology
study also indicate that transurethral collagen denaturation
does not preclude subsequent surgery for SUI if a patient
so desires. These traits make this procedure an attractive
nonsurgical treatment option for women with SUI who have
failed conventional conservative therapies but who cannot
u n d e r g oo rw i s ht oa v o i ds u r g e r y .
5. Conclusions
Results from this 36-month study show that woman who
underwent nonsurgical transurethral collagen denaturation
experienced signiﬁcant and durable improvements in QOL.
The long-term durability of this minimally invasive proce-
dureinwomenwithSUIduetobladderoutlethypermobility
indicates that transurethral collagen denaturation may be a
beneﬁcial intervention for women with this condition who
wish to avoid or postpone surgery. The results also conﬁrm
that the treatment has a good safety proﬁle, with no serious
adverse events reported at any time during this or previous
trials.
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